{"analyses":[{"ciLowerLimit":"0.45","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.76","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.58","statisticalComment":"HR and CI are from stratified Cox proportional hazard model","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.53","upperLimit":"6.67","value":"5.49"},{"groupId":"OG001","lowerLimit":"2.73","upperLimit":"4.73","value":"3.84"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"301"},{"groupId":"OG001","value":"152"}],"units":"Participants"}],"description":"Progression-free survival (PFS) is defined as the time from randomization to the date of progression or death due to any cause, whichever occurs first. 95% CI was obtained using Brookmeyer and Crowley method. Participants who are not observed to have progressed or died are censored at the date of last evaluable tumor assessment. Disease progression assessed as per RECISIST 1.1 was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with Adagrasib tablet or capsule orally at a starting dose of 600 mg twice a day (BID).","id":"OG000","title":"Adagrasib"},{"description":"Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with intravenous infusion of Docetaxel at 75 mg/m\\^2 over 1 hour or according to institutional practices.","id":"OG001","title":"Docetaxel"}],"paramType":"MEDIAN","populationDescription":"Intent-To-Treat Population includes all participants who are randomized into this study.","reportingStatus":"POSTED","timeFrame":"From randomization to the date of progression or death due to any cause, whichever occurs first (up to approximately 143 weeks)","title":"Progression-Free Survival (PFS) as Per Blinded Independent Central Review","type":"PRIMARY","unitOfMeasure":"months"}